Clinical Trial Update: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of talazoparib in advanced or recurrent solid tumors shows safety data and preliminary activity; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Ewing Sarcoma
• Or Recurrent Solid Tumors
• Ovarian Cancer Epithelial
• Pancreas Cancer
• Prostate Cancer
• Small Cell Lung Carcinoma

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Advanced or Recurrent Solid Tumors, Breast Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-01-10